{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:59:51Z","timestamp":1785898791582,"version":"3.56.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin represent a novel class of medications to manage type 2 diabetes through urinary excretion of glucose. These drugs block glucose reabsorption by the kidneys to increase glucosuria. These drugs provide hemoglobin A1C reduction, promote weight loss, and remain hypoglycemic-neutral when not used in combination with insulin or secretagogues. Canagliflozin and empagliflozin have shown cardiovascular benefit. The potential to reduce the risk of cardiovascular death in patients with type 2 diabetes, along with the benefit of weight reduction, makes these new agents useful tools for the primary care provider.<\/jats:p>","DOI":"10.1097\/01.jaa.0000533660.86287.04","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T02:42:30Z","timestamp":1527734550000},"page":"35-40","source":"Crossref","is-referenced-by-count":19,"title":["The role of SGLT2 inhibitors in managing type 2 diabetes"],"prefix":"10.1097","volume":"31","author":[{"given":"Velen","family":"Tat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Forest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230817","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1478-7954-8-29","article-title":"Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence","volume":"8","author":"Boyle","year":"2010","journal-title":"Popul Health Metr"},{"key":"R4-20230817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dc18-Sint01","article-title":"American Diabetes Association. Standards of medical care in diabetes\u20142018","volume":"41","author":"Riddle","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"R7-20230817","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-017-0280-5","article-title":"Achievement of glycated hemoglobin goals in the US remains unchanged through 2014","volume":"8","author":"Carls","year":"2017","journal-title":"Diabetes Ther"},{"issue":"4","key":"R8-20230817","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"issue":"1","key":"R9-20230817","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142018 executive summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"issue":"2","key":"R10-20230817","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"issue":"6","key":"R15-20230817","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.clinthera.2015.03.004","article-title":"The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes","volume":"37","author":"Whalen","year":"2015","journal-title":"Clin Ther"},{"issue":"5","key":"R16-20230817","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"issue":"22","key":"R17-20230817","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"R18-20230817","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"R19-20230817","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"issue":"10","key":"R20-20230817","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/ijcp.12675","article-title":"The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus","volume":"69","author":"Brunton","year":"2015","journal-title":"Int J Clin Pract"},{"issue":"2","key":"R21-20230817","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2042018814560735","article-title":"Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus","volume":"6","author":"Liakos","year":"2015","journal-title":"Ther Adv Endocrinol Metab"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01720610-201806000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T23:17:15Z","timestamp":1692314235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201806000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000533660.86287.04","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}